Crossfiled3 outlets · first filed 3 hours ago
Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim
Shkreli was banned from the pharmaceutical industry after a trial found that he organized an illegal scheme to perpetuate a monopoly for the drug Daraprim.
What the coverage shows
All three outlets center the FTC and seven states’ contempt claim that Shkreli violated a lifetime pharmaceutical-industry ban. CNBC is the only one to add a reminder of the earlier Daraprim monopoly case, while The Guardian US uniquely frames the ban as part of his 2022 release conditions and notes it covered ownership stakes and business decisions. The Hill emphasizes the alleged conduct with “flagrantly and repeatedly” from the filing.
Written by Crossfiled from the 3 headlines and extracts below, not from the articles themselves. It describes how the outlets framed this, not what happened. Open any headline for a summary of that article.
How it broke
Get the 5 stories every outlet is covering, every morning. Free.
One email a day. Unsubscribe in one click. We host no journalism and never sell your address.
More on Courts & Justice
- Supreme Court Will Review Dispute Over Records From Elon Musk’s DOGE 5 outlets
- I’m Navi Pillay’s biographer. Here’s what I learnt about the Nobel Peace Prize winner 5 outlets
- Judge blocks Trump admin. from felling trees at D.C. golf course 4 outlets
- Selma Blair leaves court after arrest over violence on flight 4 outlets
- Judge halts Trump administration's taxpayer-funded ads 4 outlets
- Russell Brand goes on trial to face rape and sexual assault charges 2 outlets